查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1641794

全球疫苗佐劑市場（按類型、疾病和應用）機會分析和產業預測，2024-2035 年

Vaccine Adjuvants Market By Type (Immunostimulants, Vehicles and Mucosal Adjuvants), By Disease (Infectious Diseases, Others), By Application (Research, Commercial): Global Opportunity Analysis and Industry Forecast, 2024-2035
出版日期: | 出版商: Allied Market Research | 英文 339 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

疫苗佐劑市場規模預計在 2023 年將達到 8.202 億美元，到 2035 年將達到 13.0483 億美元，2024 年至 2035 年的複合年成長率為 3.9%。

疫苗佐劑是一種添加到疫苗中的物質，用於增強人體對目標抗原的免疫反應，從而產生更強、更快、更持久的免疫力。從功能上看，佐劑透過模仿感染訊號發揮作用，透過刺激免疫細胞或活化特定的免疫途徑促使免疫系統產生保護性反應。這種反應可以提高疫苗的有效性，並減少抗原的數量或接種次數。載體佐劑增加抗原的穩定性和運輸，增強免疫系統的辨識和反應。

疫苗佐劑市場-IMG1

佐劑的優點是能夠增強老年人和免疫力缺乏的個體的免疫力，並提供多種病原體的廣泛保護。佐劑類型包括鋁鹽（明礬），由於其安全性和有效性而被廣泛使用；油包水乳劑，如MF59和AS03，可增強抗原的吸收；以及較新的類型，如基於脂質體、皂素和奈米顆粒的佐劑，可提供靶向遞送和控制釋放。佐劑類型在有效疫苗的開發中起著關鍵作用，因為它們是根據其增強特異性目標疾病的免疫反應的能力來選擇的。

疫苗佐劑市場受到對更有效疫苗日益成長的需求的推動，特別是針對新出現的感染疾病和慢性病。流感、肝炎、新冠肺炎和各種細菌感染疾病等感染疾病率的不斷上升推動了對疫苗的需求，凸顯了對提供廣泛保護的創新疫苗解決方案的需求。例如，根據世界衛生組織（WHO）2023年發表的一篇論文，西太平洋地區有1.16億人患有B型肝炎，1000萬人患有C型肝炎。這一發病率凸顯了對有效疫苗和支持免疫反應的佐劑的持續需求，特別是在高風險族群中，從而推動了疫苗佐劑市場的成長。

疫苗佐劑可以增強對抗原的免疫反應，潛在地提高疫苗的有效性並減少所需的劑量，這在醫療保健有限的地區尤其有益。此外，政府資金和支持疫苗開發的舉措也在疫苗佐劑市場的成長中發揮重要作用。世界衛生組織（WHO）等組織和各國政府正投入疫苗研究和生產，以提高全球免疫率。例如，2023年8月，美國衛生與公眾服務部宣布透過NextGen計畫提供超過14億美元的資金。其中包括10億美元用於疫苗臨床試驗、3.26億美元用於新型單株抗體療法，以及1億美元用於研究新型疫苗技術，以推進COVID-19疫苗開發和治療方法。

此外，製藥公司和研究機構之間日益增多的合作也促進了功效和安全性更高的新型佐劑的開發。例如，2023 年 10 月，SPI Pharma, Inc. (SPI) 和 Q-Vant Biosciences, Inc. 合作，利用 Q-Vant 在獨特和永續皂素萃取技術方面的領導地位，將 SPI 的服務和專業知識提供給全球製藥業。擴大高純度皂素商業規模 GMP 生產的投資承諾和獨家商業協議將確保全球製藥公司能夠獲得永續和完全整合的皂素佐劑供應。此類夥伴關係正在加速研發，推動疫苗佐劑市場的成長。

然而，預計與研究、開發和生產相關的高成本將抑制市場成長。佐劑開發需要大量投入專門的技術，並進行嚴格的測試以確保安全性和有效性，這增加了生產成本。對於許多公司來說，這些高昂的初始成本構成了進入壁壘，限制了市場參與企業並減少了競爭。此外，疫苗佐劑的監管要求嚴格，特別是在核准標準嚴格的地區，這進一步限制了市場的成長。

然而，新興經濟體疫苗接種計劃的不斷增加以及對個人化和治療性疫苗的關注進一步增強了市場的成長機會。隨著越來越多的製藥和生技公司開始投資新的輔助技術，以滿足多樣化和日益成長的醫療保健需求。此外，疫苗研發的進步和新興國家的高成長潛力為市場成長提供了機會。

疫苗佐劑市場根據類型、疾病、應用和地區進行細分。根據類型，市場分為免疫促效劑和載體/黏膜佐劑。活化部分進一步分為 Toll 樣受體 (TLR) 和其他。根據疾病，市場分為感染疾病和其他疾病。感染疾病部分進一步分為肝炎和其他疾病。根據應用，市場分為研究和商業。依照地區，分析分為北美（美國、加拿大、墨西哥）、歐洲（德國、法國、英國、義大利、西班牙和其他歐洲國家地區）、亞太地區（日本、中國、印度、澳洲、韓國和其他亞太地區）、拉丁美洲（巴西、哥倫比亞、阿根廷和其他拉丁美洲地區）以及中東和美洲（海灣合作理事會、阿根廷和其他拉丁美洲地區）。

相關人員的主要利益

  • 該報告對 2023 年至 2035 年疫苗佐劑市場的細分市場、當前趨勢、估計和動態進行了定量分析，並確定了疫苗佐劑市場的突出市場機會。
  • 它為市場研究提供與市場促進因素、市場限制因素和市場機會相關的資訊。
  • 波特五力分析強調了買家和供應商的潛力，使相關人員能夠做出利潤驅動的商業決策並加強供應商-買家網路。
  • 對疫苗佐劑市場區隔的詳細分析有助於確定市場機會。
  • 每個地區的主要國家都根據收益貢獻進行分類。
  • 市場公司的定位有利於基準化分析，並能清楚了解市場公司的當前地位。
  • 報告包括區域和全球疫苗佐劑市場趨勢、主要企業、細分市場、應用領域和市場成長策略的分析。

此報告可進行客製化（需支付額外費用和時間表）

  • 國家、地區和全球層面的患者/流行病學資料
  • 監管指南
  • 根據客戶興趣提供額外的公司簡介
  • 按國家或地區進行的額外分析 - 市場規模和預測
  • 擴展公司簡介列表
  • 歷史市場資料
  • SWOT 分析

目錄

第 1 章 簡介

第 2 章執行摘要

第3章 市場概況

  • 市場定義和範圍
  • 主要發現
    • 關鍵影響因素
    • 重大投資機會
  • 波特五力分析
  • 市場動態
    • 驅動程式
      • 感染疾病率上升
      • 擴大疫苗和感染疾病資金投入
      • 擴大疫苗接種計劃
    • 限制因素
      • 初期及研發成本高
    • 機會
      • 新興市場的成長機會
      • 疫苗佐劑研究進展

第4章 疫苗佐劑市場類型

  • 概述
  • 活化
    • 活化疫苗佐劑市場（按類型）
  • 載體/黏膜佐劑

第 5 章 疫苗佐劑市場（依疾病）

  • 概述
  • 感染疾病
    • 感染疾病疫苗佐劑市場（按類型）
  • 其他

第6章疫苗佐劑市場（依應用）

  • 概述
  • 研究
  • 商業的

7. 疫苗佐劑市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲
    • 巴西
    • 哥倫比亞
    • 阿根廷
    • 其他拉丁美洲國家
  • 中東和非洲
    • Gcc
    • 南非
    • 北非
    • 其他中東和非洲地區

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 前 10 家公司的產品圖譜
  • 競爭儀錶板
  • 競爭熱圖
  • 2023年主要企業的定位

第9章 公司簡介

  • Dynavax Technologies Corporation
  • Novovax Inc.
  • Agenus Inc.
  • Adjuvatis
  • Aurorium
  • InvivoGen
  • Croda International Plc
  • Air Liquide Group
  • Associated British Foods
  • GlaxoSmithKline plc.
簡介目錄
Product Code: A01341

The vaccine adjuvants market was valued at $820.2 million in 2023 and is estimated to reach $1,304.83 million by 2035, exhibiting a CAGR of 3.9% from 2024 to 2035.

Vaccine adjuvants are substances added to vaccines to enhance the body's immune response to the target antigen, allowing for a stronger, faster, or more prolonged immunity. Functionally, adjuvants work by stimulating immune cells or activating specific immune pathways, by mimicking infection signals that prompt the immune system to initiate a protective response. This response can improve the efficacy of vaccines, reducing the amount of antigen needed or the number of doses required. Vehicular adjuvants enhance stability, transport the antigen, and facilitate the immune system's recognition and response.

Vaccine Adjuvants Market - IMG1

Adjuvants offer advantages such as boosting immunity in older or immunocompromised individuals and enabling broad protection against multiple pathogens. Types of adjuvants include aluminum salts (alum), which are widely used for their safety and efficacy; oil-in-water emulsions like MF59 and AS03, which enhance antigen uptake; and novel types such as liposomes, saponins, and nanoparticle-based adjuvants that offer targeted delivery and controlled release. The adjuvant types are selected based on their ability to enhance immune responses specific to the disease being targeted, thus playing a crucial role in developing effective and efficient vaccines.

The vaccine adjuvants market is driven by rise in demand for more effective vaccines, especially in emerging infectious diseases and chronic conditions. Rise in incidence of infectious diseases, including flu, hepatitis, COVID-19, and various bacterial infections, emphasize the need for innovative vaccine solutions that rovide broad protection,thereby driving the demand for vaccines. For instance, according to an article published by World Health Organization (WHO) in 2023, 116 million people were living with hepatitis B and 10 million with hepatitis C in the Western Pacific Region. This incidence highlights the ongoing need for effective vaccines and adjuvants to support immune responses, particularly in high-risk populations, thereby driving the vaccine adjuvants market growth.

Vaccine adjuvants enhance the immune response to antigens, making vaccines more effective and potentially reducing the number of doses required, which is particularly beneficial in regions with limited healthcare access. In addition, the government funding and initiatives supporting vaccine development also play a significant role in the growth of the vaccine adjuvants market. Agencies such as the World Health Organization (WHO) and governments globally are investing in vaccine research and production to improve global immunization rates. For instance, in August 2023, the U.S. Department of Health and Human Services announced over $1.4 billion in funding through Project NextGen. This includes $1 billion for vaccine clinical trials, $326 million for new monoclonal antibody treatments, and $100 million to explore novel vaccine technologies, aimed at advancing COVID-19 vaccine development and therapeutics.

In addition, rise in collaborations between pharmaceutical companies and research institutions is leading to the development of new adjuvants with enhanced efficacy and safety. For instance, in October 2023, SPI Pharma, Inc., (SPI) and Q-Vant Biosciences, Inc. partnered to leverage Q-Vant's leadership in unique, sustainable saponin extraction technology with SPI's global pharmaceutical reach and expertise in servicing the industry. The investment commitment to expand commercial-scale GMP manufacturing of high-purity saponins, along with the exclusive commercial agreement, will enable global pharma customers to access a sustainable, scalable, and fully integrated supply of saponin adjuvants. These partnerships are accelerating research and development, thus propelling the growth of the vaccine adjuvants market.

However, high costs associated with research, development, and production are expected to restrain the market growth. Adjuvant development requires significant investment in specialized technologies and stringent testing to ensure safety and efficacy, which increases manufacturing costs. For many companies, these high initial costs pose a barrier to entry, limiting the number of players in the market and reducing the competitive landscape. In addition, stringent regulatory requirements for vaccine adjuvants, particularly in regions with rigorous approval standards, further restrict the market growth.

However, rise in vaccination programs in emerging countries, along with a focus on personalized and therapeutic vaccines, further enhance growth opportunities for the market, as more pharmaceutical and biotech companies invest in new adjuvant technologies to meet diverse and growing healthcare needs globally. In addition, rise in advancements in vaccine development and high growth potential in emerging countries provide an opportunity for the market growth.

The vaccine adjuvants market is segmented into type, disease, application, and region. By type, the market is bifurcated into immunostimulants and vehicles & mucosal adjuvants. The immunostimulants segment is further classified into toll-like receptor (TLR) and others. By disease, the market is segregated into infectious diseases and others. The infectious diseases segment is further classified into hepatitis and others. By application, the market is bifurcated into research and commercial. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India,Australia, South Korea, and rest of Asia-Pacific), and Latin America (Brazil, Colombia, Argentina, and Rest of LA), and Middle East Africa (GCC, South Africa, North Africa, and Rest of MEA).

Major key players that operate in the global vaccine adjuvants market are Dynavax Technologies Corporation , Novovax, Agenus Inc., Adjuvatis, Air Liquide Group, Aurorium, InvivoGen, Associated British Foods, GlaxoSmithKline plc., and Croda International Plc. Key players operating in the market have adopted agreement, acquisition, partnership, clinical trials, and product approval as their key strategies to expand their product portfolio. For instance, in May 2024, Novavax, Inc. entered into a co-exclusive licensing agreement with Sanofi. The terms of the agreement include a co-exclusive license to co-commercialize Novavax's current stand-alone adjuvanted COVID-19 vaccine worldwide.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vaccine adjuvants market analysis from 2023 to 2035 to identify the prevailing vaccine adjuvants market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the vaccine adjuvants market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global vaccine adjuvants market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Type

  • Immunostimulants
    • Type
    • Toll like receptor
    • Others
  • Vehicles and Mucosal Adjuvants

By Disease

  • Infectious Diseases
    • Type
    • Hepatitis
    • Others
  • Others

By Application

  • Research
  • Commercial

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Colombia
    • Argentina
    • Rest of Latin America
  • Middle East and Africa
    • Gcc
    • South Africa
    • North Africa
    • Rest of Middle East And Africa

Key Market Players:

    • Agenus Inc.
    • Novovax Inc.
    • Aurorium
    • Air Liquide Group
    • Adjuvatis
    • InvivoGen
    • Associated British Foods
    • GlaxoSmithKline plc.
    • Croda International Plc
    • Dynavax Technologies Corporation

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate intensity of rivalry
    • 3.3.2. Moderate bargaining power of buyers
    • 3.3.3. Moderate bargaining power of suppliers
    • 3.3.4. High threat of new entrants
    • 3.3.5. Moderate threat of substitutes
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in prevalence of infectious diseases
      • 3.4.1.2. Growing funding for vaccines and infectious diseases
      • 3.4.1.3. Expansion of vaccination programs
    • 3.4.2. Restraints
      • 3.4.2.1. High initial and R&D cost
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunities in emerging markets
      • 3.4.3.2. Advancements in vaccine adjuvant research

CHAPTER 4: VACCINE ADJUVANTS MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Immunostimulants
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. Immunostimulants Vaccine Adjuvants Market by Type
  • 4.3. Vehicles and Mucosal Adjuvants
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: VACCINE ADJUVANTS MARKET, BY DISEASE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Infectious Diseases
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
    • 5.2.4. Infectious Diseases Vaccine Adjuvants Market by Type
  • 5.3. Others
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: VACCINE ADJUVANTS MARKET, BY APPLICATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Research
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Commercial
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country

CHAPTER 7: VACCINE ADJUVANTS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Disease
    • 7.2.4. Market size and forecast, by Application
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Type
      • 7.2.5.1.2. Market size and forecast, by Disease
      • 7.2.5.1.3. Market size and forecast, by Application
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Type
      • 7.2.5.2.2. Market size and forecast, by Disease
      • 7.2.5.2.3. Market size and forecast, by Application
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Type
      • 7.2.5.3.2. Market size and forecast, by Disease
      • 7.2.5.3.3. Market size and forecast, by Application
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Disease
    • 7.3.4. Market size and forecast, by Application
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Type
      • 7.3.5.1.2. Market size and forecast, by Disease
      • 7.3.5.1.3. Market size and forecast, by Application
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Type
      • 7.3.5.2.2. Market size and forecast, by Disease
      • 7.3.5.2.3. Market size and forecast, by Application
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Type
      • 7.3.5.3.2. Market size and forecast, by Disease
      • 7.3.5.3.3. Market size and forecast, by Application
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Type
      • 7.3.5.4.2. Market size and forecast, by Disease
      • 7.3.5.4.3. Market size and forecast, by Application
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Type
      • 7.3.5.5.2. Market size and forecast, by Disease
      • 7.3.5.5.3. Market size and forecast, by Application
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Type
      • 7.3.5.6.2. Market size and forecast, by Disease
      • 7.3.5.6.3. Market size and forecast, by Application
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Disease
    • 7.4.4. Market size and forecast, by Application
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Type
      • 7.4.5.1.2. Market size and forecast, by Disease
      • 7.4.5.1.3. Market size and forecast, by Application
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Type
      • 7.4.5.2.2. Market size and forecast, by Disease
      • 7.4.5.2.3. Market size and forecast, by Application
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Type
      • 7.4.5.3.2. Market size and forecast, by Disease
      • 7.4.5.3.3. Market size and forecast, by Application
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Type
      • 7.4.5.4.2. Market size and forecast, by Disease
      • 7.4.5.4.3. Market size and forecast, by Application
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Type
      • 7.4.5.5.2. Market size and forecast, by Disease
      • 7.4.5.5.3. Market size and forecast, by Application
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Type
      • 7.4.5.6.2. Market size and forecast, by Disease
      • 7.4.5.6.3. Market size and forecast, by Application
  • 7.5. Latin America
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Disease
    • 7.5.4. Market size and forecast, by Application
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Type
      • 7.5.5.1.2. Market size and forecast, by Disease
      • 7.5.5.1.3. Market size and forecast, by Application
      • 7.5.5.2. Colombia
      • 7.5.5.2.1. Market size and forecast, by Type
      • 7.5.5.2.2. Market size and forecast, by Disease
      • 7.5.5.2.3. Market size and forecast, by Application
      • 7.5.5.3. Argentina
      • 7.5.5.3.1. Market size and forecast, by Type
      • 7.5.5.3.2. Market size and forecast, by Disease
      • 7.5.5.3.3. Market size and forecast, by Application
      • 7.5.5.4. Rest of Latin America
      • 7.5.5.4.1. Market size and forecast, by Type
      • 7.5.5.4.2. Market size and forecast, by Disease
      • 7.5.5.4.3. Market size and forecast, by Application
  • 7.6. Middle East and Africa
    • 7.6.1. Key market trends, growth factors and opportunities
    • 7.6.2. Market size and forecast, by Type
    • 7.6.3. Market size and forecast, by Disease
    • 7.6.4. Market size and forecast, by Application
    • 7.6.5. Market size and forecast, by country
      • 7.6.5.1. Gcc
      • 7.6.5.1.1. Market size and forecast, by Type
      • 7.6.5.1.2. Market size and forecast, by Disease
      • 7.6.5.1.3. Market size and forecast, by Application
      • 7.6.5.2. South Africa
      • 7.6.5.2.1. Market size and forecast, by Type
      • 7.6.5.2.2. Market size and forecast, by Disease
      • 7.6.5.2.3. Market size and forecast, by Application
      • 7.6.5.3. North Africa
      • 7.6.5.3.1. Market size and forecast, by Type
      • 7.6.5.3.2. Market size and forecast, by Disease
      • 7.6.5.3.3. Market size and forecast, by Application
      • 7.6.5.4. Rest of Middle East And Africa
      • 7.6.5.4.1. Market size and forecast, by Type
      • 7.6.5.4.2. Market size and forecast, by Disease
      • 7.6.5.4.3. Market size and forecast, by Application

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Dynavax Technologies Corporation
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Novovax Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Agenus Inc.
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Adjuvatis
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
  • 9.5. Aurorium
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Key strategic moves and developments
  • 9.6. InvivoGen
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
  • 9.7. Croda International Plc
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Air Liquide Group
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Associated British Foods
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. GlaxoSmithKline plc.
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments